Jain Dharmendra, Dorwal Pranav, Pande Amit, Tyagi Neetu, Mehra Simmi, Raina Vimarsh
Department of Pathology and Laboraotry Medicine, Molecular Genetics Laboratory, Medanta-The Medicity, Gurgaon, Haryana, India.
Asian J Transfus Sci. 2017 Jul-Dec;11(2):171-179. doi: 10.4103/0973-6247.214355.
Various methods have been reported for the detection of antibodies in recipient sera, which can be human leukocyte antigens (HLAs) or non-HLA specific, complement- or noncomplement fixing, as well as donor T (HLA-Class-I) and/or B cell (HLA-Class-I and II) specific. These alloantibodies play a pivotal role in antibody-mediated renal transplantation rejection. Deposition of C4d in peritubular capillaries of a kidney biopsy is a marker of antibody-mediated rejection. The C4d flow-panel reactive antibodies (PRAs) are a screening method for HLA-specific and complement fixing antibodies. However, the method is limited by the lack of donor specificity.
Here, we present a new and simple flow cytometric method referred to as C4d-flow cytometry crossmatch (C4d-FCXM) for the detection of donor-specific (T and/or B cell) and C4d-fixing alloantibodies.
The method was applied in a series of clinical cases and judged to be useful. The method may limit unwanted deferral of the donor due to positivity in C4d Flow-PRA and/or FCXM and may be helpful in prediction of antibody mediated rejections. Furthermore, this method can provide information pretransplant in contrast to kidney biopsy and C4d evaluation done posttransplant.
We postulate that this method incorporates most of the features of all the available modalities (i.e., National Institute of Health-complement dependent lymphocytotoxicity, FCXM, cytotoxic FCXM and C4d-flowPRA) yet cost-effective and best suited for resource-limited laboratory/ies which is a common scenario in developing countries.
已报道多种检测受者血清中抗体的方法,这些抗体可以是人类白细胞抗原(HLA)特异性或非HLA特异性、补体结合或非补体结合的,以及供体T细胞(HLA - I类)和/或B细胞(HLA - I类和II类)特异性的。这些同种异体抗体在抗体介导的肾移植排斥反应中起关键作用。肾活检中肾小管周围毛细血管内C4d的沉积是抗体介导排斥反应的一个标志物。C4d流式细胞仪检测群体反应性抗体(PRA)是一种检测HLA特异性和补体结合抗体的筛查方法。然而,该方法受缺乏供体特异性的限制。
在此,我们提出一种新的、简单的流式细胞术方法,称为C4d流式细胞术交叉配型(C4d - FCXM),用于检测供体特异性(T细胞和/或B细胞)和C4d结合的同种异体抗体。
该方法应用于一系列临床病例,被判定是有用的。该方法可能会减少因C4d流式PRA和/或FCXM阳性导致的供体不必要延迟,并且可能有助于预测抗体介导的排斥反应。此外,与移植后进行的肾活检和C4d评估相比,该方法可以在移植前提供信息。
我们推测该方法融合了所有现有检测方法(即美国国立卫生研究院补体依赖淋巴细胞毒性试验、FCXM、细胞毒性FCXM和C4d - 流式PRA)的大多数特征,且具有成本效益,最适合资源有限的实验室,这在发展中国家是常见情况。